Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cardiovascular secondary prevention].

H-J Rupprecht1

  • 1GPR Gesundheits- und Pflegezentrum Rüsselsheim gGmbH, August-Bebel-Strasse 59, 65428 Rüsselsheim, Germany.

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|October 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Troponins as biomarkers for myocardial injury and myocardial infarction].

Herz·2019
Same author

[Acute coronary syndrome with ST-elevation].

Herz·2019
Same author

[Antithrombotic treatment in acute coronary syndrome].

Deutsche medizinische Wochenschrift (1946)·2014
Same author

[Interventional treatment in acute coronary syndrome].

Deutsche medizinische Wochenschrift (1946)·2014
Same author

58-year-old patient with cardiac arrest due to coronary spasm.

Clinical research in cardiology : official journal of the German Cardiac Society·2007
Same author

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.

The European journal of health economics : HEPAC : health economics in prevention and care·2006
Same journal

Right ventricular dysfunction: an overlooked predictor of sudden cardiac death and arrhythmic events-a meta-analysis.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Risk factors of atrial fibrillation progression in patients with congenital heart disease.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Evaluation of neutrophil oxidative burst capacity in relation to major adverse cardiac events and infection in patients with cardiovascular disease.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Uric acid and subclinical atherosclerosis: distinct associations across coronary and carotid arteries.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same journal

Real-world characteristics and management of ventricular tachycardias in ICD patients: Data from the VIDEO registry.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
See all related articles

Effective cardiovascular secondary prevention strategies are crucial for an aging population. Lifestyle changes and targeted medications like statins, fibrates, omega-3 fatty acids, ACE inhibitors, beta-blockers, and aspirin significantly reduce cardiovascular event risk.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Context:

  • Aging global population necessitates enhanced cardiovascular secondary prevention.
  • Healthcare system reorganization is vital for prioritizing high-risk patients.
  • Lifestyle modifications are foundational for effective pharmacotherapy.

Purpose:

  • To outline essential strategies for cardiovascular secondary prevention.
  • To detail the role of various pharmacological agents in managing cardiovascular risk.
  • To emphasize the importance of personalized risk assessment for secondary myocardial infarction.

Summary:

  • Lifestyle changes (smoking cessation, diet, weight management) are the cornerstone of cardiovascular secondary prevention.
  • Statins are central, reducing coronary events by 30%; fibrates and omega-3 fatty acids (1g EPA/DHA ethyl esters) address lipid abnormalities.

Related Experiment Videos

  • ACE inhibitors, beta-blockers, and aspirin are key therapeutic options, with treatment durations guided by clinical protocols. Risk stratification algorithms aid in predicting second myocardial infarction likelihood.

    • Impact:

    • Optimized patient outcomes through evidence-based secondary prevention protocols.
    • Reduced incidence of recurrent cardiovascular events and mortality.
    • Improved healthcare resource allocation by focusing on high-risk individuals.